call. full-year for all the joining you outlook earnings our fourth have the performance progress Thank will three quarter we quarter, and made our and discuss for priorities, our in across our XXXX Today, corporate fourth XXXX. I
call then Chief Officer, quarter Sprague, will John I turn Financial fourth results. over and review our our financial will who full-year the to
during achieving and number questions open to for and for TX of Before want I provide sales closing remarks answers, a accomplishments and the key team we XXXX. Biosystems I the call start recognizing records by
number non-COVID instrument full-year record TXDx revenue achieved Sepsis Sepsis Commercially, we record that related full-year XXXX of contracts. product revenue and and a product is driven
sepsis quarter note high with test on fourth also We year ended sales. the U.S. a record
our clinical panel the our we panel, operating and and trial advanced reduced of the pipeline, reduce evaluation to the With the to mission Operationally, Panel is transformative, our we panel. way TXCandida for around the program the Panel, completed to Breakthrough FDA the Clinical patients support medicine the TXResistance product completed independent TXBiothreat headcount. and U.S. of These Device expenses we fundamentally LymeX our practiced world. TXBacteria new manufacturing the improve and a cost diagnostics TXLyme lives the designation for accomplishments change for received the through Award and culture
the patient products mortality are they outcomes, The COVID-XX essential targeted receive will which understanding faster treatment. rates. emphasized before rapid of costs of will our markets, improved the that In patient diagnosis enable to we now disease, and lead to and Sepsis status our believe each Pandemic lower therapy that target Lyme reduced include
cause is positioned to the and to the each number one nearly XX cause days. annually, requiring XX be billion within to $XX Sepsis in lives of days I'd number costing the readmitted of challenges and Sepsis like Biosystems uniquely the claiming XX XXX,XXX approximately in Americans presents annually, of hospitals, one lives one of XX% healthcare Sepsis U.S., within hospitalization the survivors day readmissions, be to claiming In year. one and systems TX nearly approximately Lyme system approximately address disease. to death our provide of million opportunity Sepsis readmitted of the XX% XX greatest background number hospital on healthcare worldwide, cause is the
older of XXXX Angeles and to the between These The hospitals nearly Los COVID-XX. elevates developed in Last died in the as at are also the adults everywhere. itself especially XX% California hospitalized, patients a of had patients infection COVID-XX in that be among California XX% Times figures XXXX who severe reported who while increase everyone Sepsis of risk should Sepsis, hospitals month, Sepsis number XXXX. unacceptable same highlighted report who
the cases administer broad are antimicrobial protocols these the growing only in of one risk antimicrobial sepsis to of threat of incurred can on current of protocols approximately care optimal to contribute fact half standard at The despite for resistance. therapy, patients relies that and
standard two which the has turn culture identify blood widely infection, have one, presence also current in And positive delayed a can which blood of care cause can a or The is false result treatment. bloodstream to false to five on which limitations, positive, days culture two, targeted poor relies blood known take culture positive results. can of to one negative to sensitivity,
genes Sepsis of can to to up rapid is data that increased improving targeted Sepsis treatment decisions achieving shows antibiotic For of and treatment causing that patient to risk outcomes. delayed antimicrobial pathogens patients, demonstrating detection of each targeted hour X%, and lead mortality resistance critical
transmitted disease. infection market Given is humans our disease common in to get target development by The progress and the in the bacterial include XXX,XXX considered infected United is Bacteria have year Lyme Lyme our illness expanded and most the Centers vector Control for to the CDC is caused the United with a noted Borrelia we or US. the borne bite ticks. approximately TXLyme Panel, may Borrelia Prevention, Lyme each of through burgdorferi States. disease States. Americans Disease
can Lyme relies used recommended a the infection, diagnostic headache, detect fatigue skin to If need untreated, heart infection joints, Lyme spread six only system. after unmet on CDC test fever, a nervous include illustrating presence can and for testing The four symptoms disease Typical rash. disease. sensitive to serological weeks the current can the for to left early of be accurately significant and antibodies and
enhancing and our overuse create pipeline. our delay our our of sales; panel Panel infections, prevent corporate the we're a and three advancing in on of stakeholders, for is initial believe of treatment the value negative allow very receive one, will therapy We detect patients focused data on ensure three, the TXLyme delivery antibiotics. faster, our and to operations; impact encouraging. TXLyme two, clinicians appropriate To The priorities, active accelerating performance
including starting priority recent provide on of corporate and XXXX our sales. each first an update now those priorities, I'll our plans, accelerating our progress our with
expanding hospitals. the our and instruments, TXLyme solidifying strategy installed panels plans on a our the increasing includes base on TXDx our Sepsis also go-to-market commercial with focused of products sales U.S. of targeting Panel. our direct Our for of adoption increasing force We're test emphasis while sales
team, commercial includes marketing, service, to aligned and sales, single support medical completely affairs, is which leader. and reports a Our
products, clinical reviewed publications on of the including the are our of peer Sepsis on educating use TXCandida value the consumers We panels. that support leveraging TXBacteria and focused
leaders, also traction The we're from serve Scientific on integration team I'm pleased the expanding that that KOLs market, for benefiting our as evidenced our Board XXXX, criteria in opinion models. our and gaining utilization. references increase patient our the of finish test to selection and who Advisory customers clinical key focused Sepsis are is in the or support by strong
to achieved U.S. record of or related In revenue. Sepsis XXXX, record fourth and revenue product non-COVID million, XX% of revenue XXXX, test we we quarter compared full-year and $X.X Sepsis product representing achieved growth
achieved from of also instruments States. totaling record of United XX the and We XX instruments full-year comprised from United the States outside Sepsis TXDx driven XX
our Our The TXDx and of of expanding service U.S. leading installed used to adoption evidenced the sale XX of XXX be providers products growing laboratories. hospital the instrument by was managed at instruments to of one within the base in TXDx laboratory the of U.S. internationally. XXX was of end including Sepsis the providers XXXX, a one
pleased system opportunity panels. their customers, one expanding believe instruments which large of Sepsis test for needs. to trend sold orders We're believe we account, two the continue healthcare there instrument same leading our U.S., a existing TXDx market instruments additional Pennsylvania, support the economic we of and the in the We to our of to our testing is value and clinical technology. a of Sepsis validates from Outside also
involves Our partnering target products our network strategy international sell go-to-market with countries. exclusive that distributors of in a support and
in and additional and countries products we high instruments internationally, XXXX, In distribution sold adoption to markets, in we including and networks to Europe, Scandinavian distributors expand our XXXX, adding by expanded plan value and TXDx countries XX into Africa we drive Asia-Pacific. During and further Latin commercial regions. Middle America, footprint East, introduce additional in Baltic our our South
commercial to efforts profitable in generate Ahead we areas in can XXXX, revenue. we more Looking where plan our focus
top and make increasing team integrated and to hospital clinical support with affairs drive Advisory commercial cases will the Our economic compelling use The selection increased Scientific utilization. broader with KOL, with medical account the team customers. reference our patient our equipped test and of extremely is Sepsis to existing Board priority panels data, and be
protocols hospitals will in of to XXXX. instruments treatment to management management has as the understand COVID-XX the Sepsis small the Sepsis. throughout we pandemic. We quickly, prepared continue by hospitals posed be are updated our shown TXDx And believe we that more patients driving midsize and the address We've have Sepsis challenges to been by these utilization gap widened, ability that already target successfully to in where have the customers
to guidance are XXXX, accurate our the believe our choosing we product be success focus Given provide our generate measure will of commercial accordingly. ability and we revenues, in to most
achieved $XX to compared XXXX million, the to growth Sepsis in to related and million expect $X.X of total revenue XXXX. of product million $XX we XX% XX% representing We
sale This guidance from revenue no of assumes TXSARS-CoV-X the our Panel.
by be its on TXResistance would TXBacteria product sales positive as increased of of to panels, Sepsis due a Potential expect represent We the panel. growth our TXDx by expected meaningful revenue, of both standalone clearance the a supported for the sales panel FDA instruments. product catalyst and driven to test adoption impact of
operations. second Moving enhancing to priority, our our
environment, success. economic operating current is critical our to efficiently the Given
structure, operating the second at our During which expenses. we of including now XXXX, in reductions overall cost and XXX quarter reduced employees, headcount, stands
of Chief Operations Vice a we Operations President position me. as the As Vice of President Regulatory to reductions, of our now are Quality Assurance Affairs and reporting of part and headcount eliminated the Officer result, and directly
and the and process we reduce improvements to XXXX, to TXBacteria panels efficiencies. gain During TXCandida made manufacturing costs manufacturing
improvements inspection. meet our which XXXX. limited material weeks, in sufficient these we of demand. customer believe quality volume cartridges impacting product improved begin In identified This routine we've during was believe financials expect internal that will raw margins, a gross is has We ability what to manufacture our experienced issue to contribute positively current to to we recent
that customers was to during product was inspection, distributors the As shipped this affected. identified not was in-process and
March. strong, have for result, which panels, by we a the backorder a hope while test some ship of remains our we to customer currently end of As demand
believe continue our that From our our we facilities. manufacturing to Lexington Wilmington, needs and meet will current a facilities Massachusetts perspective, with operations at we
September the in a Billerica, spaces. company to commercial lease agreement order office, in reported, and laboratory manufacturing facility to XXXX lease previously consolidate Massachusetts, in entered As a into our
Court. filed landlord alleged agreement, with company company's the the Massachusetts the of due and Landlord's lease In Superior to the allegations the and January the terminated The in with subsequently complaint deposit. the breach XXXX, filed contract the the landlord disagrees landlord obligations to alleging counterclaim March a on drew its unlawfully landlord's under in and breached response a complaint security XXXX and the that fact a the
breaching trade practices. fair dealing, and engaging addition of covenants and misrepresentations, to deceptive its in faith fraudulent making In good unfair and
sheet we balance Finally, gross raising the $XX strengthened during million by first of in our quarter XXXX, proceeds.
with plan our existing our to our resources with will and We execute to leverage on operating our increase commercial growth runway. extend be cash continue and disciplined expenses revenue operating
to our advancing technology Moving third both we're of pipeline, multiple platform that our priority, expertise. scientific our our and the new products leverage development advancing
milestone $XX Our million all based BARDA to the Advanced product by U.S. development are is up which product at is to contract pipeline us Research valued supported by a Development or exercised. Authority, Biomedical if options awarded
product developing and a next one, new new focused on pipeline panel. test the on instrument, test two menu goals generation to developing instrument sepsis Our two, the is TXDx comprehensive tests expand and
pathogens menu to harmful In the cleared faster Panel clinicians allow CDC, rapidly aimed anthrax, the that at is the targeted Biothreat by a identify melioidosis, The typhus. new to potentially a TXDx simultaneously cause molecular developing therapy. test designed differentiated tularemia, from detect as on the achieve representing six and plague solution and including instrument, near-term, TXBiothreat each tests our we're blood to FDA five diagnostic organisms pathogens glanders, identified direct threats expanding
these play role emergency central diagnostic with can In of rates impact. expected mortality in and in health public to pathogens is infections involving event promptly, Biothreat rapid treated not testing and XX%. minimizing economic the health XX% pathogens, result a to If of accurate a
recently target have completed high all evaluation the sensitivity announced exceeding performance six We results targets very and the and U.S. that clinical requirements. across Biothreat demonstrated specificity
and the for FDA protecting pleased deliberate the with and goal we have the regulatory naturally filing with clearance pursuing our outbreaks of of very to from pathogens. commercial or occurring sales subsequently the submission are with We shifted U.S. Americans the threat Biothreat results of focus
under the simultaneously cause XX to designed diagnostic wait funded BARDA. been five has known Panel TXResistance genes a positive to a just blood to molecular resistance Panel TXBiothreat direct infections in from culture. days three resistant and with The contract without is blood to hours detect antibiotic test our antibiotic for The need
such The is as resistance that carbapenems, and Europe TXResistance Panel, antimicrobials and detects in which Mark under vancomycin. methicillin marketed resistance sold may common CE to confer genes
patient trial file the during plan study. the our enrollment submission to of quarter complete to upon FDA of approximately second U.S. clinical We X,XXX expect ongoing completion to our patients and in the
test the TXResistance FDA, prioritized under bacteria reminder, signs major is granted disease of direct been As contract United from upon a Device designed Breakthrough process of the that cause to Panel and early provides with burgdorferi, molecular a diagnosis a of was the symptoms TXLyme blood disease Lyme review the Panel TXLyme States. TXResistance disease. funded has The with individuals for Lyme in BARDA. test The designation by to which Panel our Panel submission. The is detect diagnostic Borrelia the in and the Lyme aid intended is
six to the over of provide TXLyme a antibodies advantage the presence the testing four weeks recommended take to significant will believe Panel can post currently create that We the infection. which requires serological body
Device prioritized a Breakthrough TXLyme submission and the we U.S. the upon from patent designation the process Office to Panel. granted covering Trademark the FDA for the XXXX, review allowing for Patent and received a TXLyme Panel FDA During
Service announced TXLyme the in we in was largest and U.S. of between private a Cohen partnership for Alexandra addition, Lyme the that winner Human up includes & Health Steven and disease $XX Department the public the Panel partnership to Innovation the Foundation, funding. million LymeX, also as In known that a Accelerator, Lyme
laboratory test is TXCandida support a commence as submission developed to detected expand direct that the the to test Auris Panel panel a of add from trial commercialization is Candida to diagnostic FDA and we a clearance. the the panel. pathogens Our commence to subsequently plan molecular U.S. plan for on number TXLyme blood of clinical to test
all difficult Candida Auris some to and methods are standard resistant the identify According by as is antifungals. to CDC lead treatment laboratory recognized a multidrug of classes health inappropriate is with to can available strains serious which Candida global pathogen threat. resistant a Auris CDC, three to
is significant existing blood panel pathogens provide test panel TXBacteria on from test Acinetobacter our that We based diagnostic molecular to will believe to adding the a advantage expand culture Candida add methods. TXCandida the detected of to baumannii to blood panel. Auris compared a time number other plan the we direct to
bacteremia been Acinetobacter bloodstream to transit ill have range from infections, which benign baumannii especially to critically can mortality has of shock to XX% XX%. patients, cause crude can reported septic rate in ICU and
States carbapenems, be with or diabetes. highlighting Acinetobacter of immune and infections rarely disproportionately occur impact the including lung those antibiotics, outside systems, can in of the many chronic healthcare United to disease and rapid weakened importance can targeted resistant settings Acinetobacter detection antimicrobial treatment.
comprehensive next Longer-term, single targets ability a instrument, access, to a products, incorporates turnaround instrument automated fully our including random an and generation we're developing Sepsis to The sample. our times a new next faster test but panel. is detect be from whole similar Sepsis blood increased instrument of TXDx generation to and number the and designed
approximately resistance than comprehensive a and detect identified antibiotic our genes in test hours. time direct of instrument test BARDA. been single greater species by comprehensive generation have Sepsis contract Bacterial with Test XX% the to and The of bloodstream The Sepsis is Panel from CDC and all infections to caused designed threats funded next Candida blood result with three a under by panel a as
the BARDA XB. a currently of extension under with XA the contract, Option in TXResistance Option filing to successfully no under base clinical operating for X, anticipate X and development We're completion phase, X time the trial. milestones Option having met cost U.S. Option allow We BARDA the all Option of
resume Option Further Option funding and exercise X from X. the completion BARDA may following BARDA's of of
BARDA not providing this uncertain timing, at on the are XXXX revenue guidance Given time. we
our of Sprague financial a John? turn update quarter detailed I'll fourth for results over outlook to the XXXX. financial provide that, our John to call and With
